CD4 and neoplasm: Indeed, studies demonstrate that pharmacologic and genetic inhibitions of Axl increased the number of tumor-infiltrating cDCs [55,76,77,84] and the number of tumor-infiltrating CD4+ T-cells [55,76,77] (Table 2).